
On Monday this week, CEO Dorte X. Gram's belief in Pila Pharma's future manifested itself strongly, as she purchased a considerable portion of shares increasing her ownership to almost a third, the firm reported in a press release on Tuesday.
The former Novo Nordisk researcher founded the diabetes firm in 2016 with the focus on developing a tablet treatment for type 2 diabetes. With her purchase of 31,570 shares at SEK 6.5 (USD 0.75) per share, she now owns 31.25 percent of shares in Pila Pharma, which went public on the Nasdaq First North Growth Market in summer.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app